Luis Antonio Meillón‐García
Luis Antonio Meillón‐García publishes mostly in Hematology, Internal Medicine and Public Health, Environmental and Occupational Health, on topics such as Venous Thromboembolism Diagnosis and Management, Acute Myeloid Leukemia Research and Blood Coagulation and Thrombosis Mechanisms.
- World rank
- #4,263,696 of 7,710,434 ranked researchers
- Rank in Mexico
- #16,314 of 55,557
- Works
- 25
- Citations
- 722
- Citations per work
- 28.9
What does Luis Antonio Meillón‐García research?
Luis Antonio Meillón‐García's work is mostly in Medicine (60%).
Their six largest subfields, inside their fields and domains; the grey slice is everything else they publish. The interactive view splits every one of their works down to single topics.
The fields and subfields, with their numbers
- Health Sciences1560.5%
- Medicine1560.5%
- Everything else1039.5%
- 1Hematology24% of their works
- 2Internal Medicine11% of their works
- 3Public Health, Environmental and Occupational Health9% of their works
- 4Genetics8% of their works
- 5Rheumatology4% of their works
- 6Oncology4% of their works
Research topics
- Venous Thromboembolism Diagnosis and Management
- Acute Myeloid Leukemia Research
- Blood Coagulation and Thrombosis Mechanisms
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Trauma, Hemostasis, Coagulopathy, Resuscitation
- Chronic Myeloid Leukemia Treatments
- Atrial Fibrillation Management and Outcomes
Which keywords describe Luis Antonio Meillón‐García's research?
The keywords of their largest research topics: Antithrombotic Therapy, Prognostic Factors, Pulmonary Embolism, Venous Thromboembolism, Acute Myeloid Leukemia, AML, Acute Lymphoblastic Leukemia and Childhood Cancer.
- Atrial Fibrillation
- Trauma
- Coagulopathy
- Myelofibrosis
- Thrombin
- Childhood Cancer
- Acute Myeloid Leukemia
- Venous Thromboembolism
- Prognostic Factors
- Antithrombotic Therapy
- Pulmonary Embolism
- AML
- Acute Lymphoblastic Leukemia
- Protease-Activated Receptors
- JAK2 Mutation
- BCR-ABL
- Imatinib
- Anticoagulant Therapy
Size is their works in the topics tagged with each word, from their 8 largest topics. Each links to the topic it comes from most. The words come from the keyword list OpenAlex gives each topic, not from the text of the papers, so a word can appear that none of the papers uses.
All 18 words, with their numbers
- Antithrombotic Therapy122 topics
- Prognostic Factors112 topics
- Pulmonary Embolism71 topic
- Venous Thromboembolism71 topic
- AML61 topic
- Acute Myeloid Leukemia61 topic
- Acute Lymphoblastic Leukemia51 topic
- Childhood Cancer51 topic
- Protease-Activated Receptors51 topic
- Thrombin51 topic
- JAK2 Mutation41 topic
- Myelofibrosis41 topic
- BCR-ABL31 topic
- Coagulopathy31 topic
- Imatinib31 topic
- Trauma31 topic
- Anticoagulant Therapy21 topic
- Atrial Fibrillation21 topic
Where does Luis Antonio Meillón‐García work?
Luis Antonio Meillón‐García's main affiliation in the publication record is Centro Médico ABC, Mexico.
How many publications and citations does Luis Antonio Meillón‐García have?
OpenAlex counts 25 works and 722 citations for Luis Antonio Meillón‐García, an h-index of 8, ranking #4,263,696 of 7,710,434 researchers worldwide on the quality score.
Ranked on field-normalised citation excellence (50%), output (30%) and citations (20%). Counts come from OpenAlex author records, which occasionally merge different people who share a name or split one person into several.
Papers, co-authors, who cited this work and researchers on the nearest topics have tabs of their own, above. Is this your page? Claim it with your ORCID iD, or request a correction or removal.
Discussion
Ask a question or share a note about Luis Antonio Meillón‐García. Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.